# Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment

> **NCT00614939** · PHASE3 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 572 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Saxagliptin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00614939
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-01
- **Primary completion:** 2009-06
- **Final completion:** 2010-03
- **Target enrollment:** 572 (ACTUAL)
- **Last updated:** 2011-05-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00614939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00614939, "Treatment Effect of Saxagliptin Compared With Placebo in Patients With Type 2 Diabetes and Renal Impairment". Retrieved via AI Analytics 2026-09-08 from https://api.ai-analytics.org/clinical/NCT00614939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*